J3385 HCPCS Level II code: Injection, velaglucerase alfa, 100 units
J3385 is the HCPCS code for “Injection, velaglucerase alfa, 100 units” in CMS’s October 2026 release, in effect from Oct 1, 2026.
Official description
J3385Injection, velaglucerase alfa, 100 units
Short description: Velaglucerase alfa
HCPCS · United States
Medicare details
The indicators CMS publishes with J3385 in its October 2026 file. They describe Medicare’s handling, not another payer’s.
- Medicare coverage
- Carrier judgment
- Medicare pricing
- Drugs
- ASC
- Approved for ambulatory surgical centers
- Type of service
- Medical care; Lump sum purchase of DME, prosthetics, orthotics
- BETOS category
- Other drugs
- Added
- Jan 1, 2011
Where J3385 sits
- 1J codesDrugs administered other than orally
- 2Active code J3385Injection, velaglucerase alfa, 100 units
Source and release
- Data release
- HCPCS Level II · October 2026
- Effective date
- Oct 1, 2026
- Publisher
- CMS
This page is built from the HCPCS Level II catalog that Vero Codes reads when it suggests codes: Centers for Medicare & Medicaid Services’s October 2026 release, imported from the publisher’s file and checked against it. The description, notes and structured data come from the same record.
Frequently asked questions
What does HCPCS code J3385 mean?
J3385 is the HCPCS code for “Injection, velaglucerase alfa, 100 units” in CMS’s HCPCS Level II October 2026 release.
Does Medicare cover J3385?
CMS lists J3385’s Medicare coverage as “Carrier judgment” and its pricing as “Drugs”. Coverage and payment still depend on the patient, the setting, the documentation and the payer.
Which HCPCS Level II release does this page use?
It uses CMS’s October 2026 release, in effect from Oct 1, 2026 to Dec 31, 2026. It is a reference: confirm the code against the current list and the payer’s rules before you submit it.
Codes beside J3385
All J codesJ3373Injection, vancomycin hydrochloride, 10 mgJ3374Injection, vancomycin hydrochloride (mylan) not therapeutically equivalent to j3373, 10 mgJ3375Injection, vancomycin hydrochloride (tyzavan), not therapeutically equivalent to j3373, 10 mgJ3376Injection, vancomycin hcl (hikma), not therapeutically equivalent to j3373, 10 mgJ3379Injection, valproate sodium, 5 mgJ3380Injection, vedolizumab, intravenous, 1 mgJ3386Injection, etuvetidigene autotemcel, per treatmentJ3387Injection, elivaldogene autotemcel, per treatmentJ3389Topical administration, prademagene zamikeracel, per treatmentJ3391Injection, atidarsagene autotemcel, per treatmentJ3392Injection, exagamglogene autotemcel, per treatmentJ3393Injection, betibeglogene autotemcel, per treatment